

1 **Genome-wide insights into the shared genetic landscape between metabolic**
2 **dysfunction-associated fatty liver disease and cardiovascular diseases**

3 Jun Qiao^{1,2,9}, Miaoran Chen^{3,9}, Minjing Chang^{4,9}, Wenjia Xie³, Wenqi Ma³, Tongtong
4 Yang³, Qianru Zhao³, Kaixin Yao³, Xichen Yang³, Quan Yun³, Jing Xiao^{2,5}, Xu He^{2,5},
5 Wen Su^{6*}, Tao Xu^{7,8*}, Yuliang Feng^{1,10*}, Meixiao Zhan^{2,5*}

6 ¹ Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong
7 Universities for Vascular Homeostasis and Diseases, School of Medicine, Southern
8 University of Science and Technology, Shenzhen, China.

9 ² Guangzhou First People's Hospital, the Second Affiliated Hospital, School of
10 Medicine, South China University of Technology, Guangzhou, China.

11 ³ Department of Nephrology, Shanxi Kidney Disease Institute, Second Hospital of
12 Shanxi Medical University, Taiyuan, China.

13 ⁴ School of Public Health and Emergency Management, School of Medicine,
14 Southern University of Science and Technology, Shenzhen, China.

15 ⁵ Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and
16 Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan
17 University, Zhuhai, China.

18 ⁶ Department of Pathophysiology, Shenzhen University Health Science Center,
19 Shenzhen University, Shenzhen, China.

20 ⁷ Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui
21 Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,
22 China.

23 ⁸ Institute for Liver Diseases of Anhui Medical University, Hefei, China.

24 ⁹These authors contributed equally to this work.

25 ¹⁰Lead Contact.

26

27 ***Corresponding author:**

28 Meixiao Zhan MD, PhD

29 Professor

30 Guangzhou First People's Hospital, the Second Affiliated Hospital, School of

31 Medicine, South China University of Technology, Guangzhou, 510006, China.

32 Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and

33 Treatment, Zhuhai People's Hospital, Zhuhai Clinical Medical College of Jinan

34 University, Zhuhai, 510009, China.

35 Tel:+86-(020)81048319

36 Email: zhanmeixiao@ext.jnu.edu.cn

37

38 Yuliang Feng MD, PhD

39 Associate Professor

40 Department of Pharmacology, School of Medicine; Southern University of Science

41 and Technology, Shenzhen, Guangdong, 518055, China.

42 Tel:+86 (755)-88012564

43 Email: fengyl@sustech.edu.cn

44

45 Tao Xu PhD

46 Professor

47 Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui

48 Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei,

49 230032, China.

50 Institute for Liver Diseases of Anhui Medical University, Hefei, 230032, China.

51 Tel: +86 (0551)-65172131

52 Email: xutao@ahmu.edu.cn

53

54 Wen Su MD, PhD

55 Associate Professor

56 Department of Pathophysiology, Shenzhen University Health Science Center,

57 Shenzhen University, Shenzhen, 518071, China.

58 Tel:+86 18188610625

59 Email: suwen@szu.edu.cn

60

61 **Keywords:** Metabolic dysfunction-Associated fatty liver disease, Cardiovascular
62 diseases, genome-wide association studies, Shared genetic architectures, Genetic
63 pleiotropy.

64

65 Abstract: 275 words

66 Electronic word count manuscript: 4,568 words

67 Main figures and tables: 4 main figures, 1 main tables

68 Supplementary material: 2

69

70 **Conflict of interest statement**

71 All authors declare no competing interests.

72

73 **Financial support statement**

74 This study was supported by the Natural Science Foundation of China Excellent
75 Young Scientists Fund (Overseas) (Grant no. K241141101), Guangdong Basic and
76 Applied Basic Research Foundation for Distinguished Young Scholars (Grant no.
77 2024B1515020047), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research
78 General Projects of Shenzhen Science and Technology Innovation Commission (Grant
79 no. JCYJ20230807093514029) (To Y.F.), Shenzhen University 2035 Program for
80 Excellent Research 8690200000314, the Shenzhen Science and Technology Fund for
81 Distinguished Young Scholars (RCYX20231211090127031) (to W. S.), National
82 Natural Science Foundation of China (Grant no. 82230067, 82272103), the

83 Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and
84 Treatment (Grant no. 2021B1212040004), and the Natural Science Foundation of
85 Guangdong Province of China (Grant no. 2022B1515020010) (To M.Z.), Shenzhen
86 Science and Technology Program (Grant No. GJHZ20240218111401002 to J.B.), and
87 Center for Computational Science and Engineering at Southern University of Science
88 and Technology. The funder had no role in the design, implementation, analysis,
89 interpretation of the data, approval of the manuscript, and decision to submit the
90 manuscript for publication.

91

92 **Author contributions**

93 J.Q., M.C., M.C., Y.F., and M.Z. as conceptualization and supervised this project and
94 wrote the manuscript. W.X., W.M., T.Y., Q.Z., and K.Y. performed the main analyses
95 and wrote the manuscript. X.Y, Q.Y., J.X., and X.H. performed the statistical analysis
96 and assisted with interpreting the results. W.S., T.X., Y.F., and M.Z. provided expertise
97 in cardiovascular biology and GWAS summary statistics. All authors provided
98 intellectual content and approved the final version of the manuscript.

99 **Abstract**

100 **Background& Aims** : Multiple epidemiological studies have suggested an association
101 between Metabolic dysfunction-associated fatty liver disease (MAFLD) and
102 cardiovascular diseases (CVDs). However, the genetic components that are shared
103 between the two remain unclear.

104 **Methods:** This genome-wide pleiotropic association study integrated comprehensive
105 genome-wide association studies (GWAS) summary data from publicly available
106 sources within European populations. It employed a range of genetic approaches to
107 analyze the shared genetic architectures between MAFLD and six CVDs: atrial
108 fibrillation (AF), coronary artery disease (CAD), venous thromboembolism (VTE),
109 heart failure (HF), peripheral artery disease (PAD), and stroke. Initially, we examined
110 the genetic correlation and overlap between these conditions. Subsequently,
111 Mendelian Randomization (MR) analysis was conducted to investigate potential
112 causal relationships. Finally, we explored horizontal pleiotropy at the levels of single
113 nucleotide polymorphisms (SNPs), genes, and biological pathways to further
114 elucidate the shared genetic mechanisms underlying.

115 **Results:** We observed significant genetic associations between MAFLD and four
116 CVDs, including CAD, HF, PAD, and VTE. However, we noted extensive genetic
117 overlap in all but MAFLD-AF. MR analysis established causal relationships from
118 MAFLD to both AF and PAD. Regarding horizontal pleiotropy, 49 pleiotropic loci
119 were identified at the SNP level with functional annotations, 13 demonstrating strong
120 evidence of colocalization. At the gene level, 14 unique pleiotropic genes were found ,

121 with SAMM50 (located at 22q13.31) being particularly notable. Further pathway
122 enrichment analysis indicated that these genes significantly contribute to the pathway
123 of establishment of protein localization to membrane, highlighting their pivotal role in
124 the pathophysiology of both MAFLD and CVD.

125 **Conclusions** : In all, our research proved the shared genetic architectures and
126 mechanisms between MAFLD and CVD and elucidated their shared genetic etiology
127 and biological mechanisms.


128

129 **Impact and implications**

130 Metabolic dysfunction-associated fatty liver disease (MAFLD) has reached a
131 prevalence of 25-30% worldwide and has emerged as a global leading cause of
132 liver-related morbidity and mortality. Studies have shown that people with MAFLD
133 have a higher risk of cardiovascular disease (CVD) than the general population and
134 there is currently no effective drug to treat the comorbidity of the two, which imposes
135 a burden on the socioeconomic situation and the adverse effects are still rising.
136 Therefore, it is critical to understand how MAFLD affects CVD. Our study provides
137 unique insights into the mechanisms of comorbidity between MAFLD and CVD. The
138 increasing number of complications has prompted us to explore new treatment options,
139 so our study has important clinical significance.

140

141 **Graphical abstract**



142

143

144 **Highlights:**

- 145 ● The first comprehensive and systematic study to explore the common genetic
- 146 components between MAFLD and CVD.
- 147 ● MAFLD and CVDs share genetic architectures and mechanisms.
- 148 ● Genetically predicted MAFLD increases the risk of AF and PAD.
- 149 ● The effects of *SAMM50* (located at 22q13.31) on lipid metabolism support the
- 150 comorbidity of MAFLD and CVDs.
- 151 ● The localization of lipid droplet related contact site proteins to the membrane
- 152 plays a key role in the comorbidity of MAFLD and CVD.

153 **Introduction**

154 Non-alcoholic fatty liver disease (NAFLD) encompasses a range of liver disorders,
155 from simple steatosis to non-alcoholic steatohepatitis, fibrosis, and cirrhosis, typically
156 arising without significant alcohol consumption. According to a recent consensus
157 statement by an international panel of experts, Metabolic dysfunction-Associated fatty
158 liver disease (MAFLD) has been proposed as a more appropriate and comprehensive
159 term to replace NAFLD, better reflecting its association with known metabolic
160 dysfunctions^{1,2}. MAFLD has emerged as a global leading cause of liver-related
161 morbidity and mortality³. While liver-related complications significantly elevate
162 mortality rates, cardiovascular diseases (CVDs) remain the primary cause of death in
163 patients with MAFLD⁴. Clinically, individuals with MAFLD often exhibit elevated
164 triglyceride levels and an increased concentration of residual lipoprotein particles,
165 thereby elevating their risk for CVDs⁵. Lipoproteins containing apolipoprotein C3
166 (ApoC3) have been shown to activate the IL(interleukin)-1 to IL-6 to CRP
167 (C-Reactive Protein) inflammatory pathway, which is implicated in the development
168 of coronary artery disease (CAD), venous thromboembolism (VTE), Stroke, and
169 vascular inflammation⁶. A meta-analysis of 16 observational studies, encompassing
170 34,043 patients over a median follow-up of 6.9 years, reported a 64% increased risk
171 of fatal and/or non-fatal CVD events in patients with MAFLD compared to those
172 without⁷. The strong epidemiological evidence underscores the association between
173 MAFLD and an escalated risk of CVDs, which might suggest increased genetic
174 liability to CVD in subgroups of patients with MAFLD.

175

176 Enhanced comprehension of the shared genetic foundations between MAFLD and
177 various CVDs could offer valuable insights into these conditions. Recent large-scale
178 genome-wide association studies (GWAS) have uncovered numerous risk loci linked
179 to both MAFLD and CVDs, identifying several shared risk loci, notably at 19p13.11
180 (*TM6SF2*)⁸ and 22q13.31 (*PNPLA3*)⁹. Increasing evidence suggests genetic overlap
181 between MAFLD and CVDs. For instance, recent data suggested weak to moderate
182 positive genetic correlations between MAFLD and CAD, heart failure (HF), and
183 Hypertension, a major risk factor for CVDs¹⁰. Genetic correlation provides a
184 summary measure of the correlation across all single-nucleotide polymorphism (SNP)
185 effect sizes. However, it cannot differentiate between genetic overlap with a
186 combination of concordant and discordant effects and a complete absence of genetic
187 overlap, frequently resulting in an estimate close to 0 in both scenarios¹¹. While
188 genetic correlation can provide evidence for overall genomic similarity between traits,
189 it does not provide information for considering biological plausibility or inferring
190 potential causal relationships¹². Previous Mendelian randomization(MR) analyses
191 investigating the link between MAFLD and CVDs have shown that the causal
192 relationship was not consistently robust due to possible bias by the presence of
193 horizontal pleiotropy or sample overlap¹³⁻¹⁵. Despite these insights, a significant
194 portion of the genetic underpinnings of MAFLD and CVDs remain elusive. Moreover,
195 individual loci associated with both conditions have not been systematically analyzed,
196 an examination of which could clarify the impact of different risk loci on the

197 comorbidities of MAFLD and CVDs, as well as identify biological pathways offering
198 therapeutic promise.

199

200 This study aims to uncover their genetic overlap beyond the genetic correlation
201 between MAFLD and six major CVDs—atrial fibrillation (AF), CAD, VTE, HF,
202 peripheral artery disease (PAD), and Stroke—by leveraging unprecedentedly large
203 GWAS summary data from European ancestry. We applied the genetic analysis
204 incorporating pleiotropy and annotation (GPA), which estimates the total number of
205 unique and shared genetic variants between pairs of traits. The relevance of mixed
206 effects has been further emphasized by Local Analysis of [co]Variant Annotation
207 (LAVA), which calculates local genetic correlations across the genome, even in the
208 presence of minimal r_g . Given that GPA and LAVA quantify total genetic overlap but
209 cannot pinpoint shared genomic loci, we subsequently utilized the Pleiotropic
210 Analysis under a Composite Null Hypothesis (PLACO) method to discover loci
211 jointly associated with MAFLD and each CVD beyond genome-wide significance, a
212 critical step for gaining biological insights. Additionally, we also utilize Latent
213 Heritable Confounder Mendelian randomization (LHC-MR) analyses to explore
214 potential causal relationships between MAFLD and CVDs, considering sample
215 overlap, bidirectional causal associations, and unobserved heritable confounders.
216 Together, these methods augment the insights gained from genetic correlation
217 analyses, shedding light on the distinct and common genetic frameworks
218 underpinning MAFLD and CVDs, with implications for how we conceptualize

219 genetic risk for the comorbidity between MAFLD and CVDs.

220

221 **Materials and methods**

222 **Data sources and quality control**

223 Genetic associations with MAFLD were derived from the largest genome-wide
224 meta-analysis to date, involving 8,434 cases and 770,180 controls from four European
225 cohorts: the Electronic Medical Records and Genomics (eMERGE) Network, the UK
226 Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium, of
227 which the diagnosis was determined based on the electronic health records of all
228 participants¹⁶. To ensure that the sample size is large enough to produce reliable
229 results, we use GWAS summary data from studies with sample sizes greater than
230 50,000. Accordingly, our study encompassed six major CVDs, including AF, CAD,
231 VTE, HF, PAD, and Stroke. Specifically, GWAS summary statistics for AF were
232 retrieved from a recent meta-analysis of six cohorts, including the Health Study
233 Nord-Trøndelag (HUNT), deCODE, Michigan Genome Initiative (MGI), DiscovEHR,
234 UKB, and AFGen consortium, comprising 60,620 cases and 970,216 controls of
235 European ancestry¹⁷. GWAS summary statistics for CAD were extracted from a
236 genome-wide meta-analysis by the CARDIoGRAMplusC4D and UKB consortium,
237 including 181,522 cases and 984,168 controls of European ancestry¹⁸. GWAS
238 summary statistics for VTE were collected from the largest meta-analysis of seven
239 cohorts to date, including 81,190 cases and 1,419,671 controls of European ancestry¹⁹.
240 GWAS summary data for HF were derived from the Heart Failure Molecular

241 Epidemiology for Therapeutic Targets (HERMES) consortium, entailing 47,309 cases
242 and 930,014 controls²⁰. GWAS summary data for PAD came from the largest
243 meta-analysis conducted on data from 11 independent cohorts, totaling 12,086 cases
244 and 499,548 controls²¹. GWAS summary data for Stroke were obtained from the
245 GIGASTROKE consortium, which included 73,652 cases and 1,234,808 controls²².
246 Detailed information about these GWAS summary data and their original publication
247 sources is available in Supplementary Table 1.

248

249 Quality control was carried out strictly for GWAS summary data per the following
250 steps before further analysis:(i) alignment with the hg19 genome assembly, and the
251 1000 Genomes Project v3 Europeans was used as the reference²³; (ii) only including
252 autosomal SNPs; (iii) SNPs with duplicate entries or missing rsIDs were eliminated;
253 (iv) SNPs with a minor allele frequency (MAF) value of 0.01 or less were excluded.
254 To ensure robust results, we normalized the GWAS summary data for all phenotypic
255 SNPs, yielding 6,479,654 common SNPs across all diseases.

256

257 **Assessing the genetic correlates of MAFLD and CVDs**

258 We employed cross-trait linkage disequilibrium score regression (LDSC) analyses to
259 assess the genetic correlation (r_g) between MAFLD and six major CVDs²⁴. LDSC, an
260 effective method for evaluating genetic correlations across the genome, utilizes the
261 linkage disequilibrium (LD) structure to estimate individual SNP effect sizes from
262 GWAS summary statistics²⁵. The method involves regression of these GWAS
263 summary statistics against LD scores derived from the European 1000 Genomes
264 Project, minimizing biases related to polygenicity, sample overlap, and population

265 stratification²⁴. Due to its complexity, the major histocompatibility complex (MHC)
266 region was excluded from our analysis. First, univariate LDSC was conducted to
267 determine the SNP-based heritability (h^2_{SNP}) for MAFLD and each CVD.
268 Subsequently, bivariate LDSC estimated the r_g between MAFLD and CVDs by
269 performing a weighted linear regression on the product of Z-scores for MAFLD and
270 CVDs against the LD scores for all available genetic variants. This approach provides
271 an unbiased estimate of r_g and reliably measures genetic correlations even in
272 overlapping samples between GWAS datasets. Genetic correlations rang from -1 to +1,
273 with values closer to the extremes indicating stronger influences, and negative values
274 suggest opposite-direction effects, while positive values indicate the same direction.
275 *P*-values below a Bonferroni-corrected significance threshold ($P = 0.05 / 6 = 8.3 \times 10^{-3}$)
276 were considered statistically significant.

277

278 To identify tissues closely associated with genetic susceptibility SNPs for MAFLD
279 and CVDs, we used LDSC applied to specifically expressed genes (LDSC-SEG)²⁶.
280 This method combines aggregate GWAS summary statistics with tissue-specific gene
281 expression data for targeted tissue enrichment analysis²⁶. Our analysis incorporated
282 various gene sets, including multi-tissue gene expression data from the GTEx project
283 (v8) and chromatin information from the Roadmap Epigenomics and ENCODE
284 initiatives^{26,27}. Using the baseline model and comprehensive gene sets, we prioritized
285 genes from GTEx based on computed t-statistics, focusing on the top 10% of
286 specifically expressed candidate genes that exhibited the highest t-statistics. The
287 *P*-value from the regression coefficient's z-score was used to determine the
288 significance coefficient, and a false discovery rate (FDR) of less than 0.05 was
289 applied to assess the significance of enriched SNPs in specific tissues.

290

291 **Estimating genetic overlap between MAFLD and CVDs**

292 To address the "missing heritability" issue in complex traits, the Genetic Analysis
293 incorporating Pleiotropy and Annotation (GPA) was specifically developed. This tool

294 was specifically designed to overcome the limitations posed by the small proportion
295 of genetic variants identified through standard approaches that account for only a
296 minimal part of the expected genetic contribution²⁸. GPA achieves this by integrating
297 diverse genomic data and annotation information, thereby enhancing the prioritization
298 of GWAS results and providing a more comprehensive estimation of genetic overlap.
299 Notably, in the absence of annotation data, GPA can infer genetic overlap using
300 p-value interactions of the corresponding phenotypes²⁸. GPA is based on key
301 assumptions regarding p-value distributions: p-values from null SNPs are expected to
302 adhere to a uniform distribution, reflecting no association, while p-values from
303 non-null SNPs are presumed to follow a beta distribution, indicating potential
304 associations. Within this framework, GPA categorizes SNPs into four groups based on
305 their p-value characteristics: π_{00} suggests no association with either trait; π_{01} denotes
306 an association exclusively with the first trait; π_{10} signifies an association solely with
307 the second trait; and π_{11} represents an association with both traits. This classification
308 can estimate $\pi_{11} / (\pi_{10} + \pi_{11} + \pi_{11})$, an important ratio indicator that represents the
309 proportion of SNPs shared by two traits, suggesting the extent to which a common
310 biological pathway may be shared between the two traits²⁸. Subsequently, the
311 likelihood ratio test (LRT) was used to assess the statistical significance of the
312 observed genetic overlap²⁸. Given the complex interrelations among SNPs, GPA
313 estimates are susceptible to biases from LD. We used PLINK1.9 for LD pruning to
314 address this, drawing on data from the 1000 Genomes Project Phase 3²³ for European
315 ancestry. We also applied a Bonferroni-corrected significance threshold for multiple
316 comparisons, set at $P = 0.05 / \text{number of trait pairs} = 0.05 / 6 = 8.3 \times 10^{-3}$.

317

318 **Calculating local genetic correlations between MAFLD and CVDs**

319 LAVA facilitates the assessment of local genetic correlations by partitioning the
320 genome into smaller regions, which enables detailed insights into the influence of
321 genetic variants on various traits at a regional level, rather than across the entire
322 genome²⁹. LAVA analyses genetic correlations within different genomic segments,

323 using the regions delineated by Werme et al. as autosomal LD blocks²⁹, characterized
324 by minimal connectivity between blocks. The genome was partitioned into 2,495
325 semi-independent regions, each approximately 1 Mb, using genotype data from the
326 1000 Genomes Project Phase 3 European ancestry as the LD reference panel and
327 MHC region (chr 6: 25-35 Mb) was excluded. In conducting the genetic association
328 study, we first performed a preliminary univariate analysis using LAVA to estimate the
329 local heritability of MAFLD and CVDs. With this step, we could identify regions that
330 showed significant signals in the local genetic analysis. We then performed bivariate
331 LAVA analyses of these regions to explore regional genetic associations between
332 MAFLD and CVDs. To ensure the statistical significance of the results, the FDR
333 method was employed to calculate the adjusted p-value. FDR less than 0.05 was
334 considered the genetic correlation of these regions to be statistically significant.

335

336 **Evaluate the causal relationship between MAFLD and CVDs**

337 The genome-wide and local genetic correlations provide insights into the shared
338 genetic basis between trait pairs, but these correlations do not imply causality in either
339 direction. To overcome these limitations, linkage disequilibrium heterogeneity causal
340 Mendelian randomization (LHC-MR) provides a more refined approach to assess
341 bidirectional causality while minimizing confounding effects³⁰. This method extends
342 traditional MR by addressing limitations of the standard two-sample MR approach,
343 such as potential sample overlap, under-utilization of genome-wide markers, and the
344 need to understand exposure-outcome relationships. LHC-MR assesses bidirectional
345 causality by categorizing associations between exposure and outcome into four
346 categories: (i) causal effect of exposure on outcome, (ii) causal effect of outcome on
347 exposure, (iii) effect of confounders whose exposure affects the outcome process

348 (vertical pleiotropy), and (iv) effect of confounders whose exposure affects the
349 outcome independently (horizontal pleiotropy³⁰). Unlike traditional MR, LHC-MR
350 utilizes all genome-wide genetic variation rather than only genome-wide significant
351 variation³⁰. To ensure the stability of the results, the Bonferroni correction
352 significance threshold was set at 4.17×10^{-3} ($P = 0.05/\text{number of trait pairs}/\text{number of}$
353 tests). When $P_{axy} < 4.17 \times 10^{-3}$ and $P_{ayx} > 0.05$, it suggests a one-way causal
354 relationship from MAFLD to CVD; conversely, when $P_{ayx} < 4.17 \times 10^{-3}$ and $P_{axy} > 0.05$,
355 it implies a one-way causal relationship from CVD to MAFLD. However, if both P_{axy}
356 and P_{ayx} , exceeding the significance threshold, it indicates bidirectional causality
357 between MAFLD and CVD. We used traditional two-sample MR techniques for
358 sensitivity analysis, including Inverse Variance Weighting (IVW), MR Egger,
359 Weighted Median, Simple Mode, and Weighted Mode. P -values below the 0.05
360 threshold were considered statistically significant.

361

362 **Identification of pleiotropic loci between MAFLD and CVDs**

363 To unravel the shared genetic mechanisms between MAFLD and six major CVDs, our
364 study employs the PLACO, extending pleiotropic analysis to the SNP level³¹. PLACO
365 utilizes the summary statistic from GWAS to calculate the test statistic for the product
366 of the Z -statistics for each SNP in the two trait analyses. This calculation is based on
367 the assumption of a mixed distribution, which allows for the assessment of SNP
368 associations across traits. Using this assumption, PLACO can rigorously analyze
369 individual SNPs by pairwise Z -statistics, categorizing the null hypothesis of

370 pleiotropy into three distinct and mutually exclusive scenarios: (i) H00, indicating no
371 association of the SNP with either trait; (ii) H10, signifying an association with the
372 first trait but not the second; and (iii) H01, representing an association with the second
373 trait but not the first. The rejection of the composite null hypothesis, which
374 encompasses all three scenarios, indicates horizontal pleiotropy, suggesting that the
375 SNP influences both traits through identical mechanisms. We applied a stringent
376 significance threshold of 5×10^{-8} to identify SNPs exhibiting statistically significant
377 pleiotropy.

378

379 **Functional annotation based on pleiotropic loci**

380 To identify and conduct independent genomic loci between MAFLD and six major
381 CVDs, we utilized the Functional Mapping and Annotation (FUMA) platform³².
382 FUMA, an online tool designed to enhance the interpretability of GWAS findings,
383 performs functional annotation of pleiotropic SNPs revealed by PLACO analysis.
384 Lead SNPs are merged to delineate distinct genomic loci in LD blocks within 500 kb
385 of lead SNPs by FUMA, utilizing default parameters and LD data from the 1000
386 Genomes Project Phase 3 European cohort. Lead SNP was further selected by $r^2 < 0.1$
387 for minimal LD in independent significant SNPs (genome-wide significance $P <$
388 5×10^{-8} and $r^2 < 0.6$), indicating higher independence from adjacent genetic variations.
389 Despite these regions potentially containing several lead SNPs, the Top Lead SNP is
390 identified with the lowest P-value within a given region. Locus was deemed novel to
391 MAFLD and CVD if they did not coincide with the loci previously reported in the

392 original GWAS.

393

394 Functional annotations for Top Lead SNPs, provided by FUMA, include Combined
395 Annotation-Dependent Depletion (CADD³³) scores, regulatory function probability
396 scores via RegulomeDB (RDB³⁴), and potential effects on gene function as annotated
397 by ANNOVAR³⁵. CADD scores, which assess the harmful impact of SNPs, are
398 utilized with a threshold: a score greater than 12.37 is considered likely to be harmful,
399 reflecting the SNP's potential to affect biological functions adversely. RDB scores,
400 ranging from 1 to 7, indicate the likelihood of an SNP being located in a regulatory
401 function area, with lower scores denoting higher functional significance. Lead SNPs
402 were annotated using ANNOVAR to evaluate their proximity to genes and potential
403 impacts on gene functions, thus providing insights into how these variants might
404 influence genetic pathways or disease mechanisms. For the identification of putative
405 causal genes, SNPs were mapped using two approaches: positional mapping within a
406 10-kb window around the SNP and eQTL mapping.

407

408 **Colocalization analysis**

409 After annotating pleiotropic loci using FUMA, we analyzed colocalization with the
410 "COLOC" R package to identify potential shared causal variants across trait pairs
411 within each locus. COLOC analysis employs Bayes factors to evaluate the likelihood
412 of shared causal variation between two sets of trait-associated loci, calculating
413 posterior probabilities (PP) for five mutually exclusive hypotheses at each locus: (i)

414 no SNP is associated with either trait (H0); (ii) a causal SNP is associated only with
415 the first trait (H1); (iii) a causal SNP is associated only with the second trait (H2); (iv)
416 each trait is influenced by independent, distinct causal SNPs (H3); and (v) a single
417 SNP acts as a causal variant for both traits (H4). Our analysis primarily focuses on
418 hypothesis H4, which posits a shared causal variant for both traits. Strong evidence of
419 colocalization at a genomic locus is indicated if the posterior probability for shared
420 causal variants (PPH4) exceeds 0.70. The SNP with the highest PPH4 within these
421 loci is identified as the candidate causal variant.

422

423 **Gene-level annotation analysis**

424 To pinpoint genes that exhibit pleiotropic effects within genomic loci, a Multi-marker
425 Analysis of GenoMic Annotation (MAGMA) was performed based on the results of
426 PLACO and individual GWAS³⁶. MAGMA, a tool rooted in multivariable regression
427 models, computes the significance of gene-trait associations by incorporating
428 principal component analysis. It then employs the F-test to ascertain p-values for each
429 gene, considering factors such as gene size, SNP count per gene, and LD among the
430 markers. Consistency in gene-based testing was ensured by defining gene boundaries,
431 which encompassed regions extending ± 10 kb from the termini of each gene. We
432 obtained MAGMA gene IDs and location data for 17,636 protein-coding genes,
433 aligning SNP locations with Human Gene Build 37 (GRCh37/hg19). The MHC
434 region (chr6: 25-35 Mb) was excluded from MAGMA's gene-based analysis.
435 Significant gene associations were identified using a stringent Bonferroni-corrected

436 threshold set at $P = 4.73 \times 10^{-7}$ ($0.05 / 17,636 / 6$), accounting for the number of
437 protein-coding genes and trait pairs analyzed.

438

439 Recognizing that MAGMA links SNPs to genes based primarily on physical
440 proximity, we extended our analysis to include the eQTL-informed MAGMA
441 (e-MAGMA)³⁷. The e-MAGMA utilizes tissue-specific eQTL data to assign risk
442 variants to presumptive genes, thereby converting genome-wide association summary
443 statistics into gene-specific metrics. This method leverages tissue-specific eQTL data
444 from the GTEx project to account for long-range regulatory effects, enhancing the
445 interpretation of GWAS association signals. MHC region (chr6: 25-35 Mb) was
446 excluded in e-MAGMA analysis results as well as MAGMA to avoid confounding
447 due to complex LD patterns. Our study utilizes the GTEx v8 comprehensive database
448 containing eQTL data from 47 different tissues, based on PLACO results, to delve
449 into gene-disease associations at a fine-grained tissue level, and to gain a more
450 detailed understanding of the tissue-specific genetic architecture behind the relevant
451 diseases. To minimize confounding factors associated with broad tissue analyses, we
452 refined our approach by selecting a subset of tissues based on insights from
453 LDSC-SEG results and previous research. Specifically, our focused analysis included
454 ten tissues: two types of adipose tissue (subcutaneous and visceral omental fat), three
455 arterial tissues (aorta, coronary, and tibial arteries), two cardiac tissues (left ventricle
456 and atrial appendage), as well as liver, EBV-transformed lymphocytes, and whole
457 blood. Using the 1000 Genomes Project v3 European samples as the LD reference, we

458 calculated tissue-specific p-values for each gene across the selected tissues. We
459 applied a Bonferroni correction to determine the significance of these p-values,
460 accounting for the number of tissue-specific protein-coding genes and trait pairs
461 examined. For instance, the significance threshold for adipose subcutaneous tissue
462 was set at $P = 0.05 / 7,560 / 6 = 1.10 \times 10^{-6}$.

463

464 To further explore tissue-specific gene-trait associations for MAFLD and CVDs, we
465 conducted a transcriptome-wide association study (TWAS) using single-trait GWAS
466 results³⁸. Employing the FUSION framework, TWAS integrates GWAS summary
467 statistics with eQTL data from the GTEx v8 dataset to assess how variations in gene
468 expression across specific tissues influence phenotypes. We used pre-computed gene
469 expression weight references from the tissues analyzed in our e-MAGMA study. LD
470 pruning was performed during the third phase of the 1000 Genomes Project using the
471 LD structures of the European subpopulation. Significance thresholds were adjusted
472 using tissue-specific Bonferroni corrections to control for multiple tests.

473

474 **Pathway level analyses**

475 We performed functional enrichment analysis on the overlapped gene lists
476 significantly identified by MAGMA and e-MAGMA analyses using the ToppGene
477 functional annotation tool (ToppFun)³⁹. ToppGene Suite is a comprehensive portal for
478 gene list enrichment analysis and candidate gene prioritization. The ToppFun
479 application provides a variety of annotation data types, including transcriptome,

480 proteome, regulatory elements (such as transcription factor binding sites (TFBS) and
481 microRNA), ontologies (such as GO and Pathway), phenotypes (including human
482 diseases and mouse phenotypes), pharmacometrics (drug-gene associations), and
483 literature co-citations. Additionally, ToppFun prioritizes candidate genes based on
484 their functional similarity to ensure rigorous and thorough analysis. Significant GO
485 terms were identified with an FDR threshold of 0.05.

486

487 **Results**

488 **SNP-based heritability and genetic correlations between MAFLD and CVDs**

489 After harmonizing and filtering SNPs common across GWAS summary statistics,
490 LDSC was utilized to estimate the h^2_{SNP} and the genome-wide genetic correlations (r_g)
491 between MAFLD and CVDs. Univariate LDSC analysis indicated that the h^2_{SNP} of
492 MAFLD was 0.002 (SE = 0.001). In comparison, the h^2_{SNP} of CVDs ranged from
493 0.008 to 0.032, with CAD exhibiting the highest heritability ($h^2_{SNP} = 0.032$, SE =
494 1.90×10^{-3}) and HF the lowest ($h^2_{SNP} = 0.008$, SE = 3.01×10^{-3}). Notably, the
495 heritability of MAFLD was lower than that of any individual CVD. Bivariate LDSC
496 revealed that all trait pairs exhibited positive genetic correlations under a relaxed
497 significance threshold ($P < 0.05$). However, four trait pairs maintained statistical
498 significance after applying a Bonferroni correction for multiple comparisons ($P <$
499 $0.05 / 6 = 8.33 \times 10^{-3}$). These findings highlight the subtle genetic interactions between
500 MAFLD and CVD, which underscores the potential for shared genetic pathways to
501 influence these complex diseases.

502

503 **Genetic overlap analysis**

504 The r_g is a vital metric that reflects the genetic relationship between trait pairs,
505 providing insights into their shared genetic architecture. Importantly, a r_g value close
506 to zero does not necessarily signify the absence of a genetic association between traits.
507 This apparent discrepancy can arise from various factors, such as the mixed effects of
508 homozygosity and reverse effects, or a lack of genetic overlap, which may mask the
509 true genetic relationships and lead to misleadingly low r_g values. Recognizing this
510 limitation highlights a "missing dimension" in our understanding of genetic
511 connections between phenotypes. To enhance our understanding of genetic
512 interactions and address these challenges, advanced statistical methods, including
513 GPA and LAVA, have been employed by us.

514

515 The intricacies of the genetic relationships observed between MAFLD and CVDs,
516 particularly the surprising contrast between significant genetic overlap and weak
517 correlation in some cases, underscore the complexity of genetic interactions and the
518 importance of considering additional analytical dimensions. In our analysis of six trait
519 pairs, the MAFLD-AF pair was the only one that failed to meet the Bonferroni
520 correction threshold, indicating a lack of significant genetic overlap. Conversely, the
521 MAFLD-CAD pair demonstrated the most significant genetic overlap, evidenced by a
522 P-value of 7.12×10^{-31} , aligning with LDSC results, which revealed the highest genetic
523 correlation ($r_g = 0.627$, $P = 5.18 \times 10^{-6}$). Although a significant genetic overlap was

524 identified between MAFLD and Stroke ($P = 6.96 \times 10^{-6}$), the minimal PAR value (PAR
525 $= 7.00 \times 10^{-4}$) highlights a small proportion of pleiotropic SNPs. Furthermore, the weak
526 genetic correlation between MAFLD and Stroke ($r_g = 0.627$, $P = 3.98 \times 10^{-2}$) suggests
527 that the presence of multiple closely linked SNPs with independent or heterogeneous
528 impacts may obscure consistent effects, resulting in a correlation that falls short of
529 higher statistical confidence thresholds. This phenomenon, where broad genetic
530 overlap coexists with weak genetic correlation, implies that mixed effects may mask
531 the true genome-wide genetic correlation.

532

533 **Regional genetic correlation analysis**

534 LAVA evaluates genetic correlations within specific genomic regions and identifies
535 subtle genetic effects that might elude detection by LDSC. This capability is vital, as
536 genetic influences often vary across the genome, and the correlations between traits
537 can differ markedly by region. First, a univariate LAVA analysis was conducted by us
538 with a strict threshold of $P < 1 \times 10^{-4}$ to identify regions with strong genetic signals,
539 resulting in the identification of 2,336 significant regions. These regions were then
540 formed into 77 bivariate test sets for more detailed analysis. In the subsequent
541 bivariate LAVA analysis, we applied a looser significance threshold ($P < 0.05$),
542 identifying approximately 22 genomic regions showing genetic signals associated
543 with all trait pairs. Notably, our LAVA analysis revealed five key genetic regions
544 associated with MAFLD and stroke, including three negatively and two positively
545 correlated regions. This discovery of substantial genetic overlap starkly contrasts the

546 lack of significant genome-wide associations found using LDSC. This discrepancy
547 between the LAVA and LDSC results underscores the complex genetic architecture,
548 suggesting that regions with both positive and negative correlations may lead to a
549 heterogeneous distribution of genetic effects. Such complexity might mask genetic
550 signals when assessed on a genome-wide scale using LDSC. We then applied a
551 stricter threshold of $P < 6.49 \times 10^{-4}$ to account for multiple comparisons. This led to
552 the identification of a significant region on chromosome 8, spanning from
553 125,453,321 to 126,766,827, showing a strong correlation between MAFLD and CAD
554 ($r_g = 0.509$, $P = 3.05 \times 10^{-6}$), aligns with the positive genetic correlation observed across
555 the genome by LDSC.

556

557 **Causal relationship linking MAFLD and CVDs**

558 The observed genetic overlap between MAFLD and CVDs extends beyond mere
559 correlation, suggesting the presence of pleiotropy. However, determining whether this
560 pleiotropy is horizontal or vertical remains unresolved. To clarify this, we utilized the
561 LHC-MR approach, which sheds light on the bidirectional causal relationships
562 between MAFLD and CVD through vertical pleiotropy. Our findings revealed a
563 significant positive causal effect of MAFLD on both AF and PAD, with odds ratios
564 (OR) of 1.11 ($P = 2.36 \times 10^{-3}$) and 1.375 ($P = 1.39 \times 10^{-4}$), respectively. These results
565 underscore MAFLD as a critical risk factor in the onset and development of both AF
566 and PAD, aligning with previous research that highlights MAFLD's role in increasing
567 the prevalence of these disorders. Notably, we found no evidence to suggest reverse

568 causality in these relationships.

569

570 **Shared variants and functional annotation of MAFLDs and CVDs**

571 To further dissect the complex genetic mechanisms between MAFLD and CVDs, we
572 utilized PLACO to identify significant pleiotropic variants indicative of horizontal
573 pleiotropy. This inquiry, through its meticulous analysis, unveiled a trove of 3,438
574 SNPs exhibiting significant pleiotropic influences. Subsequently, these SNPs
575 underwent a process of annotation, facilitated by the FUMA tool, which meticulously
576 delineated 49 distinct loci spanning 20 chromosomal regions, enriching our
577 understanding of the genetic landscape under scrutiny. Seven of the 49 loci identified
578 were novel and had not been previously associated with MAFLD or CVDs. Among
579 the 22 loci (44.9%), the selected effect alleles at the top SNPs within or near loci
580 demonstrated effect directions that were consistent with each other which means they
581 may concurrently increase ADs and CVDs or diminish the risk of developing ADs and
582 CVDs. Notably, three loci, 22q13.31, 16q12.2, and 8q24.13, were associated with
583 more than half of the trait pairs analyzed. The chromosomal region 22q13.31, in
584 particular, is implicated in five trait pairs, excluding MAFLD-Stroke, highlighting its
585 significance in the pleiotropic landscape. For example, *SAMM50* located at 22q13.31,
586 studies have shown that *SAMM50* gene polymorphisms are associated with the
587 occurrence and severity of fatty liver disease, which may be related to reduced fatty
588 acid oxidation caused by *SAMM50* deficiency⁴⁰. Although there is no direct evidence
589 linking *SAMM50* to cardiovascular disease, its potential effects on heart development

590 and function by regulating mitochondrial autophagy may influence cardiovascular
591 disease risk⁴¹. Moreover, the *FTO* gene, located in the 16q12.2 region, is another gene
592 of interest due to its impact on energy intake and expenditure, potentially increasing
593 susceptibility to both MAFLD and CVDs^{42,43}. Moreover, the *TRIB1* gene, located at
594 8q24.13, plays a critical role in regulating lipid metabolism. It influences downstream
595 signaling pathways such as PI3K-AKT and MAPK, which promote the accumulation
596 of liver lipids and increase the risk of MAFLD^{44,45}. Additionally, polymorphisms in
597 the *TRIB1* gene have been linked to an increased risk of CAD and Stroke. Specifically,
598 the A allele at rs2954029 has been significantly associated with these conditions;
599 individuals carrying the A allele exhibit a higher risk of both CAD and stroke⁴⁶.

600

601 Functional annotation via FUMA identified 24 intronic SNPs, 14 intergenic SNPs,
602 and 5 exonic SNPs. For example, the 22q13.31 region includes the exonic SNP
603 rs1007863, which showed significant eQTL associations in several tissues: adipose
604 subcutaneous ($P = 2.38 \times 10^{-6}$), adipose visceral omentum ($P = 2.16 \times 10^{-15}$), whole
605 blood ($P = 3.57 \times 10^{-5}$), artery aorta ($P = 3.57 \times 10^{-5}$), and artery tibial ($P = 1.42 \times 10^{-12}$).
606 Notably, the P-value for adipose visceral omentum was used as the P-value for this
607 region in MAFLD-AF for PLACO results, indicating that this P-value is considered
608 the most appropriate or representative indicator, suggesting that visceral tissues are
609 importantly associated with this trait pair. Seven of all pleiotropic SNPs were
610 identified as potentially deleterious, with a CADD score greater than 12.37. Notably,
611 rs28929474 exhibited the highest CADD score of 20.2, suggesting its potential

612 association with the development of MAFLD and CAD and its deleterious effects.
613 Furthermore, based on RDB scores, two SNPs were found to potentially impact
614 transcription factor binding, with rs10401969 showing the most significant effect
615 (RBD = 1f). Further colocalization analysis revealed evidence of colocalization in 13
616 of the 49 pleiotropic loci (PPH4 > 0.7). Notably, the 16q12.2 region has demonstrated
617 a robust colocalization signal across all four trait pairs it encompasses (with a
618 posterior probability of heterogeneity, PPH4, ranging from 0.766 to 0.890).

619

620 **Gene-level annotation of MAFLD and CVDs**

621 Using MAGMA, we identified 34 potential pleiotropic genes (28 of which are unique)
622 between MAFLD and CVDs after Bonferroni correction, which is situated on or
623 overlaps with 49 previously identified pleiotropic loci. Among these, 2 are novel
624 unique genes, 3 have newly unique been associated with CVDs, and 23 are newly
625 unique implicated in MAFLD. Notably, three genes—*SAMM50*, *PNPLA3*, and
626 *FTO*—were detected in two or more trait pairs. Further, of the genes identified by
627 MAGMA, 32 were corroborated by FUMA's locus mapping. The pervasive impact of
628 *SAMM50* across multiple traits underscores its significance and makes it a primary
629 focus of our ongoing investigation.

630

631 We performed tissue-specific analyses employing LDSC-SEG to identify the tissues
632 associated with each disease. After adjusting for multiple comparisons using the FDR
633 method, significant associations were observed solely with CVDs. Specifically, for AF,

634 the auricle and the left ventricle were identified as the primary tissues driving the
635 condition, suggesting that functional changes in these areas may play a crucial role in
636 its development and maintenance. Similarly, in CAD, the predominant tissues
637 associated with the disease were located in arterial regions, including the aorta,
638 coronary artery, and anterior tibial artery, with the anterior tibial artery demonstrating
639 the most significant impact. Unfortunately, while MAFLD showed enrichment in the
640 anterior cingulate cortex, cerebral cortex, and frontal cortex, these did not meet the
641 significant threshold for correction. In all, after integrating the results of tissue
642 enrichment analysis with tissues commonly implicated in clinical practice for these
643 conditions, we finally selected 10 tissues for subsequent analysis.

644

645 Given the limitations of MAGMA, which assigns SNPs based solely on proximity to
646 genes and may overlook the effects of distant gene regulation, we employed
647 e-MAGMA to overcome these deficiencies. By integrating eQTL data from 10
648 distinct tissues, e-MAGMA enabled us to identify 161 tissue-specific genes, including
649 59 that were unique. Notably, *IRAK1BP1*, *ATP13A1*, *SAMM50* and *NME7* were
650 identified in more than half of the trait pairs. *IRAK1BP1* exhibits high specificity to
651 nine tissues except EBV-transformed lymphocytes and has not previously been
652 associated with MAFLD or any CVDs. However, its involvement in inflammation
653 suggests a potential role in these diseases. Our findings were further validated using
654 FUMA's GTExV8 data through e-MAGMA, confirming the identification of 78
655 tissue-specific genes, including *SAMM50* at 22q13.31. Subsequent TWAS analysis of

656 the original GWAS results was used to validate the EMAGMA analysis, and 300
657 tissue-specific genes were identified as new genes for MAFLD and 185 as new genes
658 for CVDs.

659

660 Finally, 17 pleiotropic genes (14 unique) were identified by MAGMA and e-MAGMA.
661 *SAMM50* at 22q13.31 was the only gene that appeared in multiple trait pairs (except
662 for MAFLD-PAD and MAFLD-Stroke), while other genes appeared only in single
663 trait pairs.

664

665 **Functional enrichment analysis of pleiotropic genes in MAFLD and CVDs**

666 Understanding how identified genes collectively fulfill specific biological functions
667 through shared pathways enhances our ability to derive meaningful interpretations
668 from genomic data. The tool ToppFun assists in mapping these genes to their
669 respective enrichment pathways and biological processes, which can reveal the
670 activity levels or enrichment of certain pathways. Notably, three pathways were
671 significantly enriched: membrane organization, endoplasmic reticulum tubular
672 network organization, and the establishment of protein localization to the membrane.
673 Protein localization is critical in the accumulation of lipid droplets near mitochondria;
674 it helps protect mitochondrial function by sequestering toxic lipids. This protective
675 mechanism is crucial for managing lipid accumulation in the liver and other tissues,
676 where excessive lipid buildup can lead to MAFLD and CVDs^{47,48}. Proper protein
677 localization, therefore, plays a pivotal role in mitigating lipid toxicity and maintaining

678 cellular balance, thereby reducing the risk of both MAFLD and CVD.

679

680 **Discussion**

681 This genome-wide pleiotropic association study offers compelling evidence of a

682 shared genetic architecture and mechanisms between MAFLD and six major CVDs.

683 We observed moderate to strong genome-wide genetic associations between MAFLD

684 and four CVDs—CAD, HF, PAD, and VTE—with notable genetic overlap in all but

685 the MAFLD-AF trait pair. MR analysis provided evidence of causal relationships for

686 two trait pairs, underscoring the presence of vertical pleiotropy. Additionally, at the

687 SNP level, our cross-trait analysis pinpointed 49 pleiotropic loci, 13 demonstrating

688 strong evidence of colocalization. Further analysis at the gene level through MAGMA

689 and e-MAGMA identified 45 (34 unique) significant position-specific pleiotropic

690 genes and 161 (59 unique) tissue-specific pleiotropic genes, including 17 overlapping

691 pleiotropic genes (14 unique because *SAMM50* was identified in 4 trait pairs).

692 Moreover, at the biological pathway level, protein localization to membrane signaling

693 pathways was identified as potentially pivotal in the co-pathogenesis of MAFLD and

694 CVD. These insights not only deepen our understanding of their intertwined genetic

695 etiology but also illuminate potential targets for therapeutic intervention and

696 preventive strategies.

697

698 In our study, bivariate LDSC revealed extensive positive genetic correlations between

699 MAFLD and six major CVDs, among which only four trait pairs (including

700 MAFLD-CAD, MAFLD-HF, MAFLD-PAD, and MAFLD-VTE) passed the
701 Bonferroni correction. Further analysis using the GPA method demonstrated
702 significant genetic overlap for all pairs except MAFLD with AF, underscoring the
703 shared genetic underpinnings of these conditions. Interestingly, although no
704 significant genome-wide genetic correlation was detected between MAFLD and
705 stroke, substantial genetic overlap suggested the presence of complex genomic
706 interactions, which was also confirmed by local genetic correlations of LAVA. In the
707 MAFLD-stroke pair, we identified loci with mixed effect directions—two positively
708 and three negatively correlated—suggesting that local mixed effects might underlie
709 the non-significant genome-wide genetic correlation, potentially driven by a range of
710 pleiotropic variants¹¹. Additionally, despite the lack of a significant association
711 between MAFLD and AF in both LDSC and GPA analyses, our bivariate LAVA under
712 a loose threshold indicated a positive regional genetic correlation between the two.
713 Overall, our findings confirm that MAFLD and CVDs share substantial heritability
714 and genetic components, elucidating the genetic basis of their high comorbidity.

715

716 The shared genetic basis between MAFLD and CVD is primarily driven by horizontal
717 and vertical pleiotropy (i.e., causal relationships). We employed the LHC-MR method
718 to investigate potential causal links between MAFLD and 6 major CVDs. Our
719 analysis revealed that genetically predicted MAFLD is causally associated with an
720 increased risk of AF and PAD. These findings are consistent with prior
721 epidemiological evidence. A meta-analysis confirmed an association between

722 MAFLD and an increased risk of AF⁴⁹. Concurrently, a separate cohort study
723 observed a high prevalence of PAD among MAFLD patients over 40 years old in the
724 United States during a 13-year follow-up⁵⁰. Conversely, we found no established
725 causal relationship between MAFLD and HF or Stroke, nor was a reverse causal
726 relationship between MAFLD and CVD supported. This contrasts with earlier MR
727 analyses that reported a positive causal relationship between MAFLD and both HF¹⁵
728 and CAD¹⁴, which suggested a 15% increase in CAD incidence per unit increase in
729 MAFLD. These discrepancies may arise from limitations in previous studies, such as
730 potential genetic confounders and smaller sample sizes, which could impact the
731 reliability of the exposure-outcome relationship. LHC-MR analysis is particularly
732 effective at generating potential causal effects by excluding confounding factors, even
733 in the face of unmeasured confounding. Leveraging extensive sample data and
734 advanced methodologies, our study provided more robust and reliable causal effect
735 estimates. Our study only provides partial evidence for vertical pleiotropy, suggesting
736 that the shared genetic basis between MAFLD and CVD is primarily driven by
737 horizontal pleiotropy.

738

739 Horizontal pleiotropy analysis further elucidated the common genetic architecture
740 between MAFLD and CVD by discovering pleiotropic variants and loci, pleiotropic
741 genes, and biological pathways between the two. Further investigation through
742 horizontal pleiotropy analysis has confirmed their extensive comorbidity, identifying
743 widespread pleiotropic variants across several key loci, such as 22q13.31, 16q12.2,

744 and 8q24.13, which are prominently associated with more than half of the trait pairs
745 analyzed. Notably, the locus at 16q12.2—associated with all trait pairs except
746 MAFLD-CAD and MAFLD-Stroke—maps to the *FTO* gene. This gene plays a
747 critical role in lipid metabolism by enhancing oxidative stress and increasing
748 lipogenesis in hepatocytes, thereby exacerbating MAFLD progression⁵¹. Moreover,
749 according to a meta-analysis of 10 observational studies (19,153 CVD cases and
750 103,720 controls), variants in the *FTO* gene have been shown to significantly elevate
751 CVD risk, independent of BMI and other conventional risk factors⁵². Moreover, in a
752 large prospective longitudinal study of Type 2 diabetes (T2D) patients, variants in the
753 *FTO* gene were also found to increase the risk of myocardial infarction and
754 cardiovascular death by influencing a dyslipidemic phenotype typical of insulin
755 resistance⁵³. The above evidence suggests that the lipid metabolism process can be
756 significantly changed by affecting the expression of the *FTO* gene, thereby improving
757 MAFLD and reducing the risk of cardiovascular death.

758

759 In our gene-level analysis using MAGMA and e-MAGMA, we identified significant
760 pleiotropic genes at the 22q13.31 locus, including patatin-like phospholipase-domain
761 containing protein 3 (*PNPLA3*) and sorting and assembly machinery component 50
762 (*SAMM50*). These genes play crucial roles in the comorbidity between MAFLD and
763 CVDs. *PNPLA3*, which exhibits weak hydrolytic activity towards glycerolipids, has
764 been linked to the development of MAFLD and CVDs, excluding PAD and Stroke.
765 This gene is associated with a missense variant closely linked to triacylglycerol (TAG)

766 accumulation in the liver—a major genetic risk factor for steatotic liver diseases^{54,55}.
767 *PNPLA3* competitively displaces adipose triglyceride lipase (ATGL) from lipid
768 droplets, reducing lipolytic activity and promoting the progression of MAFLD⁵⁴.
769 Intriguingly, a GWAS meta-analysis revealed that the *PNPLA3* G-allele rs738409
770 offers modest protection against CAD by reducing triglyceride breakdown in the liver,
771 thus affecting the secretion of very low-density lipoprotein particles and the
772 development of atherosclerosis⁵⁶. Additionally, our e-MAGMA analysis identified
773 *SAMM50* at this locus as influencing most trait pairs. As an essential component of
774 the Sorting and Assembly Machinery (SAM) complex on the outer mitochondrial
775 membrane, *SAMM50* is vital for β -barrel protein biogenesis and interacts directly with
776 the translocator of the outer mitochondrial membrane (TOM) complex⁴¹. It plays a
777 significant role in fatty acid β -oxidation and, when deficient, can lead to intracellular
778 lipid accumulation, exacerbating MAFLD⁴⁰. Moreover, *SAMM50*'s involvement in
779 mitochondrial dysfunction may impair the removal of reactive oxygen species (ROS),
780 further contributing to the progression of MAFLD⁵⁷ and increasing susceptibility to
781 HF by impairing mitochondrial function⁴¹. This mitochondrial pathway regulated by
782 *SAMM50* offers a theoretical basis for the observed comorbidity between MAFLD
783 and HF in our study, underscoring the potential for targeted therapies at this genetic
784 locus.

785

786 In our pathway-level analysis, we discovered a crucial role for the gene *SAMM50* in
787 mediating protein localization to membranes, a process integral to the pathogenesis of

788 MAFLD. This protein localization is especially important in how lipid droplets
789 accumulate near mitochondria, which may protect mitochondrial function by
790 sequestering toxic lipid species. Proteins that migrate to these lipid droplets at
791 membrane contact sites are prime candidates for facilitating this protective
792 mechanism^{47,48}. In the liver, an excessive influx of lipids leads to the accumulation of
793 triglyceride (TG)-rich lipid droplets, a hallmark of MAFLD⁴⁷. Variations in genes
794 associated with lipid droplet formation, such as PNPLA3, acting as both
795 phospholipase and acyl transfer enzyme, is an important regulating factor for TG. It
796 limits the activity of triglyceride hydrolases, leading to TG accumulation in the liver,
797 thus predisposing to MAFLD⁵⁸. Moreover, when lipid droplets amass in peripheral
798 organs, the overflow of toxic lipids can contribute to CVDs. ATGL plays a pivotal role
799 in this context by hydrolyzing TG within these droplets. It activates the
800 PPAR α /peroxisome proliferator-activated receptor- γ coactivator 1 (*PGC1*) complex in
801 cardiomyocytes. A deficiency in cardiac ATGL leads to reduced *PGC1* expression,
802 resulting in mitochondrial dysfunction and lipid accumulation, which can progress to
803 HF⁵⁹. In conclusion, the localization of contact site proteins related to lipid droplets is
804 instrumental in preventing lipid overflow and safeguarding mitochondrial function.
805 This mechanism significantly reduces the risk of both MAFLD and CVD by
806 maintaining crucial cellular balances and interactions.

807

808 Our study has several limitations. First, our study population was confined to
809 individuals of European ancestry, necessitating further research across other ethnic

810 groups to determine the universal applicability of our findings. Second, the datasets
811 used for MAFLD and CVD included some cases with existing or potential co-morbid
812 conditions, which may have biased our investigation of genetic overlap. Third, our
813 analysis was limited to common genetic variants, highlighting the need for future
814 studies to explore the impact of rare variants, which may also significantly influence
815 the high comorbidity observed between MAFLD and CVD. Finally, while we
816 reported some statistically significant findings, further investigation is required to
817 assess their clinical relevance and implications.

818

819 In summary, our study demonstrates extensive genetic overlap, partial genetic
820 correlation, and causal relationships between MAFLD and six major CVDs.
821 Identification of the pleiotropic gene, *SAMM50*, at pleiotropic risk loci 22q13.31,
822 shared between MAFLD and CVD, suggesting a common biological mechanism,
823 namely the establishment of protein localization to the membrane, uncovering
824 indications of shared genetic foundation for MAFLD and CVDs. This research
825 enhances the shared genetic map of these diseases and offers new perspectives on
826 preventing and treating their co-morbidities.

827

828 **Abbreviations**

829 AF (atrial fibrillation) ApoC3 (apolipoprotein C3) ATGL (adipose triglyceride lipase)
830 CVDs (cardiovascular diseases) CAD (coronary artery disease) CRP (C-Reactive
831 Protein) CADD (Combined Annotation-Dependent Depletion) e-MAGMA
832 (eQTL-informed MAGMA) eMERGE (Electronic Medical Records and Genomics)
833 EstBB (Estonian Biobank) FUMA (Functional Mapping and Annotation) FDR (false
834 discovery rate) GPA (Genetic Analysis incorporating Pleiotropy and Annotation)
835 GWAS (genome-wide association studies) h^2_{SNP} (SNP-based heritability) HF (heart
836 failure) HUNT (Health Study Nord-Trøndelag) HERMES (Heart Failure Molecular
837 Epidemiology for Therapeutic Targets) IVW (Inverse Variance Weighting) IL-1
838 (interleukin-1) LDSC (linkage disequilibrium score regression) LD (linkage
839 disequilibrium) LDSC-SEG (LDSC applied to specifically expressed genes) LRT
840 (likelihood ratio test) LAVA (Local Analysis of [co]Variant Annotation) LHC-MR
841 (Latent Heritable Confounder Mendelian randomization) MAFLD (metabolic
842 dysfunction-associated fatty liver disease) MR (Mendelian Randomization) MGI
843 (Michigan Genome Initiative) MAF (minor allele frequency) MHC (major
844 histocompatibility complex) MAGMA (Multi-marker Analysis of GenoMic
845 Annotation) NAFLD (Non-alcoholic fatty liver disease) OR (odds ratios) PAD
846 (peripheral artery disease) PLACO (Pleiotropic Analysis under a Composite Null
847 Hypothesis) RDB (RegulomeDB) PP (posterior probabilities) *PNPLA3* (patatin-like
848 phospholipase-domain containing protein 3) *PGC1* (PPAR α /peroxisome
849 proliferator-activated receptor- γ coactivator 1) ROS (reactive oxygen species) SNPs

850 (single nucleotide polymorphisms) *SAMM50* (sorting and assembly machinery
851 component 50) SAM (Sorting and Assembly Machinery) TWAS (transcriptome-wide
852 association study) ToppFun (ToppGene functional annotation tool) TFBS
853 (transcription factor binding sites) T2D (Type 2 diabetes) TAG (triacylglycerol) TOM
854 (translocator of the outer mitochondrial membrane) TG (triglyceride) UKB (UK
855 Biobank) VTE (venous thromboembolism)

856

857 **Acknowledgements**

858 We would like to thank all GWAS authors who provided summary statistics for this
859 study. We thank the Electronic Medical Records and Genomics (eMERGE) Network,
860 the UK Biobank (UKB), the Estonian Biobank (EstBB), and the FinnGen Consortium
861 for providing us with data on MAFLD, without whom this work would not have been
862 possible. We would also like to thank the Health Study Nord-Trøndelag (HUNT),
863 deCODE, Michigan Genome Initiative (MGI), DiscovEHR, UKB, and AFGen
864 consortium for providing AF data; the CARDIoGRAMplusC4D and UKB consortium
865 for providing CAD data; the deCODE for providing VTE data; the Heart Failure
866 Molecular Epidemiology for Therapeutic Targets (HERMES) consortium for
867 providing HF data; the Cardiovascular Disease Knowledge Portal (CVDKP) website
868 for providing PAD data; and the GIGASTROKE consortium for providing stroke
869 data.

870

871 **References**

- 872 [1] Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et
873 al. A new definition for metabolic dysfunction-associated fatty liver disease: An
874 international expert consensus statement. *J Hepatol* 2020; 73: 202-9.
- 875 [2] Eslam M, Sanyal AJ, George J. MAFLD: A Consensus-Driven Proposed
876 Nomenclature for Metabolic Associated Fatty Liver Disease. *Gastroenterology* 2020;
877 158: 1999-2014.e1.
- 878 [3] Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in
879 NAFLD. *Clin Gastroenterol Hepatol* 2023; 21: 2026-39.
- 880 [4] Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related
881 mortality in non-alcoholic fatty liver disease. *J Hepatol* 2008; 49: 608-12.
- 882 [5] Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to
883 cardiovascular disease. *Mol Metab* 2020; 42: 101092.
- 884 [6] Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, et al. NAFLD and
885 cardiovascular diseases: a clinical review. *Clin Res Cardiol* 2021; 110: 921-37.
- 886 [7] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver
887 disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol* 2016;
888 65: 589-600.
- 889 [8] Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al.
890 Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic
891 steatohepatitis from cardiovascular disease. *Hepatology* 2015; 61: 506-14.
- 892 [9] Brouwers M, Simons N, Stehouwer CDA, Koek GH, Schaper NC, Isaacs A.

893 Relationship Between Nonalcoholic Fatty Liver Disease Susceptibility Genes and
894 Coronary Artery Disease. *Hepatology* 2019; 3: 587-96.

895 [10]Fang Z, Jia S, Mou X, Li Z, Hu T, Tu Y, et al. Shared genetic architecture and
896 causal relationship between liver and heart disease. *iScience* 2024; 27: 109431.

897 [11]Hindley G, Frei O, Shadrin AA, Cheng W, O'Connell KS, Ickick R, et al. Charting
898 the Landscape of Genetic Overlap Between Mental Disorders and Related Traits
899 Beyond Genetic Correlation. *Am J Psychiatry* 2022; 179: 833-43.

900 [12]Perry BI, Bowker N, Burgess S, Wareham NJ, Upthegrove R, Jones PB, et al.
901 Evidence for Shared Genetic Aetiology Between Schizophrenia, Cardiometabolic, and
902 Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses.
903 *Schizophr Bull Open* 2022; 3: sgac001.

904 [13]Hemani G, Bowden J, Davey Smith G. Evaluating the potential role of pleiotropy
905 in Mendelian randomization studies. *Hum Mol Genet* 2018; 27: R195-r208.

906 [14]Ren Z, Simons P, Wesselius A, Stehouwer CDA, Brouwers M. Relationship
907 between NAFLD and coronary artery disease: A Mendelian randomization study.
908 *Hepatology* 2023; 77: 230-8.

909 [15]Peng H, Wang S, Wang M, Ye Y, Xue E, Chen X, et al. Nonalcoholic fatty liver
910 disease and cardiovascular diseases: A Mendelian randomization study. *Metabolism*
911 2022; 133: 155220.

912 [16]Ghodsian N, Abner E, Emdin CA, Gobeil É, Taba N, Haas ME, et al. Electronic
913 health record-based genome-wide meta-analysis provides insights on the genetic
914 architecture of non-alcoholic fatty liver disease. *Cell reports Medicine* 2021; 2:

915 100437.

916 [17]Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et
917 al. Biobank-driven genomic discovery yields new insight into atrial fibrillation
918 biology. *Nature genetics* 2018; 50: 1234-9.

919 [18]Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery
920 and systematic characterization of risk variants and genes for coronary artery disease
921 in over a million participants. *Nature genetics* 2022; 54: 1803-15.

922 [19]Ghouse J, Tragante V, Ahlberg G, Rand SA, Jespersen JB, Leinøe EB, et al.
923 Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction
924 equivalent to monogenic forms of venous thromboembolism. *Nature genetics* 2023;
925 55: 399-409.

926 [20]Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, et al.
927 Genome-wide association and Mendelian randomisation analysis provide insights into
928 the pathogenesis of heart failure. *Nature communications* 2020; 11: 163.

929 [21]van Zuydam NR, Stiby A, Abdalla M, Austin E, Dahlström EH, McLachlan S, et
930 al. Genome-Wide Association Study of Peripheral Artery Disease. *Circulation*
931 *Genomic and precision medicine* 2021; 14: e002862.

932 [22]Mishra A, Malik R, Hachiya T, Jürgenson T, Namba S, Posner DC, et al. Stroke
933 genetics informs drug discovery and risk prediction across ancestries. *Nature* 2022;
934 611: 115-23.

935 [23]Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A
936 global reference for human genetic variation. *Nature* 2015; 526: 68-74.

- 937 [24]Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al.
938 LD Score regression distinguishes confounding from polygenicity in genome-wide
939 association studies. *Nature genetics* 2015; 47: 291-5.
- 940 [25]Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size
941 distributions using summary-level statistics from genome-wide association studies
942 across 32 complex traits. *Nature genetics* 2018; 50: 1318-26.
- 943 [26]Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, et al.
944 Heritability enrichment of specifically expressed genes identifies disease-relevant
945 tissues and cell types. *Nature genetics* 2018; 50: 621-9.
- 946 [27]Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis:
947 multitissue gene regulation in humans. *Science (New York, NY)* 2015; 348: 648-60.
- 948 [28]Chung D, Yang C, Li C, Gelernter J, Zhao H. GPA: a statistical approach to
949 prioritizing GWAS results by integrating pleiotropy and annotation. *PLoS genetics*
950 2014; 10: e1004787.
- 951 [29]Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework
952 for local genetic correlation analysis. *Nature genetics* 2022; 54: 274-82.
- 953 [30]Darrous L, Mounier N, Kutalik Z. Simultaneous estimation of bi-directional
954 causal effects and heritable confounding from GWAS summary statistics. *Nature*
955 *communications* 2021; 12: 7274.
- 956 [31]Ray D, Chatterjee N. A powerful method for pleiotropic analysis under composite
957 null hypothesis identifies novel shared loci between Type 2 Diabetes and Prostate
958 Cancer. *PLoS genetics* 2020; 16: e1009218.

- 959 [32]Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
960 annotation of genetic associations with FUMA. *Nature communications* 2017; 8:
961 1826.
- 962 [33]Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general
963 framework for estimating the relative pathogenicity of human genetic variants. *Nature*
964 *genetics* 2014; 46: 310-5.
- 965 [34]Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al.
966 Annotation of functional variation in personal genomes using RegulomeDB. *Genome*
967 *research* 2012; 22: 1790-7.
- 968 [35]Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
969 variants from high-throughput sequencing data. *Nucleic acids research* 2010; 38:
970 e164.
- 971 [36]de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set
972 analysis of GWAS data. *PLoS computational biology* 2015; 11: e1004219.
- 973 [37]Gerring ZF, Mina-Vargas A, Gamazon ER, Derks EM. E-MAGMA: an
974 eQTL-informed method to identify risk genes using genome-wide association study
975 summary statistics. *Bioinformatics (Oxford, England)* 2021; 37: 2245-9.
- 976 [38]Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate
977 causal variants by statistical fine-mapping. *Nature reviews Genetics* 2018; 19:
978 491-504.
- 979 [39]Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list
980 enrichment analysis and candidate gene prioritization. *Nucleic acids research* 2009;

- 981 37: W305-11.
- 982 [40]Li Z, Shen W, Wu G, Qin C, Zhang Y, Wang Y, et al. The role of SAMM50 in
983 non-alcoholic fatty liver disease: from genetics to mechanisms. *FEBS Open Bio* 2021;
984 11: 1893-906.
- 985 [41]Xu R, Kang L, Wei S, Yang C, Fu Y, Ding Z, et al. Samm50 Promotes
986 Hypertrophy by Regulating Pink1-Dependent Mitophagy Signaling in Neonatal
987 Cardiomyocytes. *Front Cardiovasc Med* 2021; 8: 748156.
- 988 [42]Patnaik D, Jena AB, Kerry RG, Duttaroy AK. In silico profiling of
989 nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on
990 the treatment of non-alcoholic fatty liver disease. *Lipids Health Dis* 2023; 22: 17.
- 991 [43]Xu ZY, Jing X, Xiong XD. Emerging Role and Mechanism of the FTO Gene in
992 Cardiovascular Diseases. *Biomolecules* 2023; 13.
- 993 [44]Bauer RC, Yenilmez BO, Rader DJ. Tribbles-1: a novel regulator of hepatic lipid
994 metabolism in humans. *Biochem Soc Trans* 2015; 43: 1079-84.
- 995 [45]Zhang T, Tan P, Wang L, Jin N, Li Y, Zhang L, et al. RNALocate: a resource for
996 RNA subcellular localizations. *Nucleic acids research* 2017; 45: D135-d8.
- 997 [46]Jiang J, Chen X, Li C, Du X, Zhou H. Polymorphisms of TRIB1 genes for
998 coronary artery disease and stroke risk: A systematic review and meta-analysis. *Gene*
999 2023; 880: 147613.
- 1000 [47]Krahmer N, Najafi B, Schueder F, Quagliarini F, Steger M, Seitz S, et al.
1001 Organellar Proteomics and Phospho-Proteomics Reveal Subcellular Reorganization in
1002 Diet-Induced Hepatic Steatosis. *Dev Cell* 2018; 47: 205-21.e7.

- 1003 [48]Nguyen TB, Louie SM, Daniele JR, Tran Q, Dillin A, Zoncu R, et al.
1004 DGAT1-Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during
1005 Starvation-Induced Autophagy. *Dev Cell* 2017; 42: 9-21.e5.
- 1006 [49]Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, et al. Risk of
1007 cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic
1008 review and meta-analysis. *Eur J Prev Cardiol* 2022; 29: 938-46.
- 1009 [50]Ciardullo S, Bianconi E, Cannistraci R, Parmeggiani P, Marone EM, Perseghin G.
1010 Peripheral artery disease and all-cause and cardiovascular mortality in patients with
1011 NAFLD. *J Endocrinol Invest* 2022; 45: 1547-53.
- 1012 [51]Guo J, Ren W, Li A, Ding Y, Guo W, Su D, et al. Fat mass and obesity-associated
1013 gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. *Dig*
1014 *Dis Sci* 2013; 58: 1004-9.
- 1015 [52]Liu C, Mou S, Pan C. The FTO gene rs9939609 polymorphism predicts risk of
1016 cardiovascular disease: a systematic review and meta-analysis. *PLoS One* 2013; 8:
1017 e71901.
- 1018 [53]Doney AS, Dannfald J, Kimber CH, Donnelly LA, Pearson E, Morris AD, et al.
1019 The FTO gene is associated with an atherogenic lipid profile and myocardial
1020 infarction in patients with type 2 diabetes: a Genetics of Diabetes Audit and Research
1021 Study in Tayside Scotland (Go-DARTS) study. *Circ Cardiovasc Genet* 2009; 2: 255-9.
- 1022 [54]Witzel HR, Schwittai IMG, Hartmann N, Mueller S, Schattenberg JM, Gong XM,
1023 et al. PNPLA3(I148M) Inhibits Lipolysis by Perilipin-5-Dependent Competition with
1024 ATGL. *Cells* 2022; 12.

- 1025 [55]Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3
1026 protein isoform (I148M) associated with nonalcoholic fatty liver disease. *J Biol Chem*
1027 2011; 286: 37085-93.
- 1028 [56]Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers M. PNPLA3,
1029 TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease. *Gastroenterology*
1030 2017; 152: 912-3.
- 1031 [57]Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, et al.
1032 Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and
1033 PARVB genes are associated with development and progression of nonalcoholic fatty
1034 liver disease in Japan. *Hum Genet* 2013; 132: 783-92.
- 1035 [58]Dai G, Liu P, Li X, Zhou X, He S. Association between PNPLA3 rs738409
1036 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and
1037 severity: A meta-analysis. *Medicine* 2019; 98: e14324.
- 1038 [59]Krahmer N, Farese RV, Jr., Walther TC. Balancing the fat: lipid droplets and
1039 human disease. *EMBO Mol Med* 2013; 5: 973-83.
- 1040

Table 1. Genetic Correlation and Genetic Overlap Estimations Between 6 Pairwise Traits^a

Trait pair	Genetic correlation			Genetic overlap			
	Genetic correlation (SE)	<i>P</i> value for LDSC	Intercept (SE)	<i>P</i> value for intercept	PM 11	PAR ^b	<i>P</i> value for GPA
MAFLD-AF	0.1381 (0.0891)	0.121	0.0080 (0.0053)	0.131	0.0000	0.0004	9.55×10 ⁻²
MAFLD-CAD ^{c,d}	0.6266 (0.1375)	5.18×10 ⁻⁶	0.0018 (0.0059)	0.760	0.0036	0.0424	7.12×10 ⁻³¹
MAFLD-HF ^{c,d}	0.5725 (0.1576)	3.00×10 ⁻⁴	0.0058 (0.0045)	0.197	0.0001	0.0010	1.12×10 ⁻¹¹
MAFLD-PAD ^{c,d}	0.6259 (0.2099)	2.90×10 ⁻³	0.0075 (0.0053)	0.157	0.0001	0.0029	1.32×10 ⁻⁰³
MAFLD-Stroke ^d	0.2783 (0.1353)	3.98×10 ⁻²	0.0057 (0.0045)	0.205	0.0001	0.0007	6.96×10 ⁻⁶
MAFLD-VTE ^{c,d}	0.4844 (0.1220)	7.19×10 ⁻⁵	0.0025 (0.0051)	0.624	0.0002	0.0025	4.66×10 ⁻¹⁰

Note:

a. Genetic correlation and genetic overlap were estimated by LDSC and GPA methods, respectively. Bonferroni-corrected significance threshold was set at $P \leq 8.33 \times 10^{-3}$ (0.05/6), producing a final union set of 5 pairwise traits with significant genetic correlation or genetic overlap for subsequent analysis.

b. We introduced PAR as $PM_{11} / (PM_{10} + PM_{01} + PM_{11})$ to represent the proportion of pleiotropic single-nucleotide variations (SNPs) associated with both traits against the proportion of SNPs associated with at least 1 trait.

c. Pairwise trait with significant genetic correlation.

d. Pairwise trait with significant genetic overlap.

Abbreviations: MAFLD, Metabolic dysfunction-Associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; HF, Heart failure; PAD, Peripheral artery disease; VTE, Venous thromboembolism; LDSC, linkage disequilibrium score regression; GPA, genetic analysis incorporating pleiotropy and annotation method; PAR, pleiotropy association ratio; PM 11, proportion of genetic variants associated with both traits.

Figure legends

Figure 1. Metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases estimated by local genetic correlation.

LAVA volcano plots showing local genetic correlation coefficients (local- r_{gs} , y-axis) for MAFLD and CVDs with $-\log_{10}$ p -values for each trait pair of analyses for each locus. Loci above the horizontal line are significant at $P < 0.05$ (negative correlation for blue dots, positive correlation for red dots). Larger points with black circles indicate loci significantly associated after Bonferroni correction ($P = 6.49 \times 10^{-4} = 0.05 / 77$). LAVA-estimated local- r_{gs} is shown on the blue-red scale. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 2. Inference of bidirectional causal relationship between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

Forest plots of the causal relationship between MAFLD and six major CVDs using the LHC-MR method. The estimates presented in the forest plot were obtained using the LHC-MR method. A positive association is indicated by the odd ratio (OR > 1), while a negative association is indicated by OR < 1 . The results of forward causality from the LHC-MR method are in the up panel, and the results of reverse causality from the LHC-MR method are in the down panel. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery

disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 3. Manhattan plots for the PLACO results of metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

Manhattan plots reflect chromosomal position (x-axis) and negative log₁₀-transformed P-values (y-axis) for each SNP. The horizontal dashed red line indicates the genome-wide significant P-value of $-\log_{10}(5 \times 10^{-8})$. The r^2 threshold for defining independent significant SNPs was set to 0.2, and the maximum distance between LD blocks merged into one locus was set to 500 kb. The independent genome-wide significant associations with the smallest P-value (Top lead SNP) are encircled in a colorful circle. Only SNPs shared across all summary statistics were included. MAFLD, metabolic dysfunction-associated fatty liver disease; AF, atrial fibrillation; CAD, coronary artery disease; VTE, venous thromboembolism; HF, heart failure; PAD, peripheral arterial disease.

Figure 4. The overall situation of the pleiotropy association between metabolic dysfunction-associated fatty liver disease and six major cardiovascular diseases.

A circular dendrogram showing the shared genes between MAFLD (center circle) and each of six CVDs (first circle), resulting in six pairs. A total of 49 shared loci were identified across six trait pairs (third circle), mapped to 45 nominally significant pleiotropic genes (34 were Bonferroni-corrected significant) identified by

multimarker analysis of GenoMic annotation (MAGMA). For the trait pairs with more than three pleiotropic genes, we only showed the top 3 pleiotropic genes according to the prioritization of candidate pleiotropic genes (fourth circle). MAFLD, metabolic dysfunction-associated fatty liver disease; AF, Atrial fibrillation; CAD, Coronary artery disease; VTE, Venous thromboembolism; HF, Heart failure; PAD, Peripheral artery disease.

Figure 1.




Figure 2.




Figure 3.







Figure 4.




MAFLD-AF




MAFLD-CAD




MAFLD-VTE




MAFLD-HF



MAFLD-PAD










MAFLD-Stroke




rho












Metabolic dysfunction-associated fatty liver disease




Cardiovascular diseases




(a) Linkage disequilibrium score regression




(b) Genetic analysis incorporating Pleiotropy and Annotation



(c) Local Analysis of [co]Variant Annotation



(d) Latent Heritable Confounder MR



(e) Pleiotropic Analysis under a Composite Null Hypothesis